Department of Geriatrics, Medical Center for Digestive Diseases, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210011, China
2.
Affiliated Cancer Hospital & Institute, Guangzhou Medical University, Guangzhou, Guangdong 510095, China
3.
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
4.
Division of General Surgery, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210011, China
5.
Department of Geriatric Gastroenterology, the First Affiliated Hospital of Nanjing Medical University, Institute of Neuroendocrine Tumor, Nanjing Medical University, Nanjing, Jiangsu 210029, China
Zhongping Su, Department of Geriatric Gastroenterology, the First Affiliated Hospital of Nanjing Medical University, Institute of Neuroendocrine Tumor, Nanjing Medical University, 300 Guangzhou Road, Gulou District, Nanjing, Jiangsu 210029, China. Tel: +86-25-68303236, E-mail: suzhping@163.com
Qiang You, Department of Biotherapy, the Second Affiliated Hospital of Nanjing Medical University, 121 Jiangjiayuan Road, Gulou District, Nanjing, Jiangsu 210011, China. Tel: +86-25-58509620, E-mail: qiang.you@njmu.edu.cn
Hepatoblastoma is the most frequent liver malignancy in children. HepG2 has been discovered as a hepatoblastoma-derived cell line and tends to form clumps in culture. Intriguingly, we observed that the addition of calcium ions reduced cell clumping and disassociated HepG2 cells. The calcium signal is in connection with a series of processes critical in the tumorigenesis. Here, we demonstrated that extracellular calcium ions induced morphological changes and enhanced the epithelial-mesenchymal transition in HepG2 cells. Mechanistically, calcium ions promoted HepG2 proliferation and migration by up-regulating the phosphorylation levels of focal adhesion kinase (FAK), protein kinase B, and p38 mitogen-activated protein kinase. The inhibitor of FAK or Ca2+/calmodulin-dependent kinase Ⅱ (CaMKⅡ) reversed the Ca2+-induced effects on HepG2 cells, including cell proliferation and migration, epithelial-mesenchymal transition protein expression levels, and phosphorylation levels of FAK and protein kinase B. Moreover, calcium ions decreased HepG2 cells' sensitivity to cisplatin. Furthermore, we found that the expression levels of FAK and CaMKⅡ were increased in hepatoblastoma. The group with high expression levels of FAK and CaMKⅡ exhibited significantly lower ImmunoScore as well as CD8+ T and NK cells. The expression of CaMKⅡ was positively correlated with that of PDCD1 and LAG3. Correspondingly, the expression of FAK was negatively correlated with that of TNFSF9, TNFRSF4, and TNFRSF18. Collectively, extracellular calcium accelerates HepG2 cell proliferation and migration via FAK and CaMKⅡ and enhances cisplatin resistance. FAK and CaMKⅡ shape immune cell infiltration and responses in tumor microenvironments, thereby serving as potential targets for hepatoblastoma.
Hepatoblastoma is the most frequent primary liver malignancy in children younger than five years old, accounting for more than 80% of all pediatric cases with liver cancer[1–2]. The incidence of hepatoblastoma is related with the Beckwith-Weidemann syndrome, familial adenomatosis polypi and low birth weight[3]. It was reported that the number of hepatoblastoma cases was rising by 2.2% each year between 2000 and 2015[4]. Current treatment includes surgical resection combined with the platinum-based chemotherapy[5]. However, therapeutic effects of advanced tumors are still far from being satisfying. Multiple drug resistance is a major factor contributing to the unfavorable prognosis of children with an advanced-stage of hepatoblastoma[6]. There is an urgent need for investigations to focuse on factors responsible for drug resistance in hepatoblastoma and on possible ways to overcome the therapy resistance. The HepG2 cell line is a hepatoblastoma cell line[7], and its genetic profile shows the presence of β-catenin mutation-related Wnt pathway activation[8].
Calcium ions (Ca2+) impact almost every aspect of cellular life[9]. In the resting state, the free calcium concentration in the cytosol is stable at approximately 100 nmol/L, which is called calcium homeostasis[9]. When cells are stimulated, cytosolic calcium concentration can increase more than 10-fold and locally up to 100- to 1 000-fold, mainly coming from outside of the cell and endoplasmic reticulum/sarcoplasmic reticulum[10]. The calcium signal is an important modulator of a spectrum of cellular processes, many of which are related to those important in cancer progression, such as proliferation and migration[11]. One concrete example of the role of calcium signaling in proliferation could be observed in early G1 of the cell cycle, where Ca2+ was linked to the expression of the early response genes, such as FOS, JUN, and MYC[11]. Ca2+ is also one of the important modulators of cell migration, and an influx of calcium ions is crucial for the migration of multiple cell types, including tumor cells[12].
Intriguingly, when performing transfection experiments on HepG2 cells using a calcium phosphate method, we noticed an obviously altered morphology of the cells. We hypothesized that the addition of calcium ions could account for the morphology change. Therefore, we examined the changes in the expression of molecules associated with adhesion and metastasis by adding different concentrations of CaCl2 to the DMEM medium supplemented with 10% fetal bovine serum (FBS). To investigate the role of extracellular calcium in proliferative and metastatic behavior, we measured cell proliferation and migration in the CaCl2-treated HepG2 cells. We also explored the molecular mechanisms by quantifying the activity of intracellular signaling pathways, particularly the activation of focal adhesion kinase (FAK) and its regulatory phosphatase Ca2+/calmodulin-dependent kinase Ⅱ (CaMKⅡ). We further explored the impact of calcium on sensitivity to the treatment of cisplatin in HepG2 cells. Moreover, we evaluated the significance of FAK and CaMKⅡ in hepatoblastoma using public database.
Materials and methods
Cell lines and culture
The HepG2, MCF-7, Caco-2, and HUVEC cell lines were obtained from the Chinese Academy of Sciences (Shanghai, China). All cell lines were cultured in the DMEM medium (Cat. #11965092, Gibco, New York, USA) supplemented with 10% FBS (Cat. #10099-141, Gibco), 100 units/mL penicillin, and 100 μg/mL streptomycin (Cat. #15140-122, Gibco), and incubated at 37 ℃ in an incubator containing 5% CO2.
Drugs and reagents
The inhibitors of FAK (PF573228; Cat. #SC1099, Beyotime, Shanghai, China), CaMKⅡ (KN93; Cat. #HY-15465, MedChemExpress, New Jersey, USA), calpeptin (MDL28170; Cat. #HY-18236, MedChemExpress), ATPase [(-)-blebbistatin; Cat. #SF9087, Beyotime], actin polymers (Cytochalasin B; Cat. #HY-16928, MedChemExpress), mitosis (Nocodazole; Cat. #S1765, Beyotime), and Rho-associated coiled kinase (ROCK; Y-27632; Cat. #SC0326, Beyotime) were used to determine the involved mechanical components[13]. Calcium chloride anhydrous (CaCl2; Cat. #C1016, Sigma, Shanghai, China), potassium chloride (KCl; Cat. #10016308, Sinapharm Chemical Reagent Co., Ltd., Shanghai, China), and magnesium chloride hexahydrate (Sinapharm Chemical Reagent Co., Ltd.) were used to treat HepG2 cells with different final concentrations.
RNA extraction and quantitative real-time PCR
Total RNA was isolated using Trizol (Cat. #15596026, Invitrogen, CA, USA) and transcribed into cDNA using the reverse transcription kit (Cat. #R323, Vazyme, Nanjing, Jiangsu, China) following the manufacturers' protocols. The cDNA was amplified with the AceQ Universal SYBR qPCR Master Mix 2X kit (Cat. #Q511, Vazyme) using the Step One Plus Real-Time PCR System (Applied Biosystems, Waltham, MA, USA). Primers were synthesized in Invitrogen (Shanghai, China) and the sequences were available in Supplementary Table 1 (available online).
Western blotting
Total proteins were obtained using the RIPA lysis buffer (Cat. #P0013C, Beyotime). The protein concentration was quantified by the bicinchoninic acid (BCA) assay kit (Cat. #23227, Thermo Scientific, Rockford, IL, USA). Then, proteins were separated using 8% to 15% SDS polyacrylamide gel electrophoresis, then transferred to PVDF membrane, and blocked in 5% bovine serum albumin (Cat. #A1933, Sigma, Louis, MO, USA). The membrane was probed with specific primary antibodies followed by horseradish peroxidase conjugated antibody. Proteins were detected by addition of ECL substrate (Cat. #34580, Thermo Fisher Scientific). The antibodies are listed in Supplementary Table 2 (available online).
Cell counting kit-8 assay
The cell counting kit-8 (CCK8) assay was carried out in line with the manufacturer's i nstructions (Cat. #CK04, Dojindi Labs, Kumamoto, Japan). The absorbance at 450 nm was determined using a spectrophotometer (Labsystems, Sweden).
EdU proliferation assay
The cell proliferation assay was conducted using the BeyoClick EdU Cell Proliferation Kit with Alexa Fluor 488 (Cat. #C0071S, Beyotime). The numbers of proliferative cells were counted by the fluorescence microscope (Olympus, Japan).
Wound healing assay
Cells were seeded in 12-well plates at 95% confluence, and then cells were scratched with a pipette tip and washed with PBS to remove the floating cells. Wounded monolayers were photographed at 12-h intervals for 72 h.
Flow cytometry analysis
HepG2 cells were harvested after treatment with or without CaCl2 for 24 h, and then incubated with human Fc receptor blocker (Clone QA19A30; Cat. #163404, BioLegend, San Diego, CA, USA) to prevent non-specific binding. The cells were then stained with PE/Cyanine7 anti-human CD274 (B7-H1, PD-L1) antibody (Clone 29E.2A3; Cat. #329718, BioLegend). The BD FACSCanto Ⅱ flow cytometer was used to perform flow cytometry, and FlowJo software (Tree Star, OR, USA) was used to analyze the data.
Data processing
RNA-seq data and corresponding clinical information on hepatoblastoma were obtained from the GEO database (GSE104766, GSE131329, GSE133039, GSE151347, and GSE38122). All expression profiles were transformed into TPM (transcripts per million transcripts). Differential gene expression analysis was performed using the R 'limma' package (https://bioconductor.org/packages/release/bioc/html/limma.html) in R. The Wilcoxon rank‐sum test was implemented to analyze the differences between different groups.
Pathway analysis
Based on the transcriptome profiling data and gene sets retrieved from Molecular Signatures Database (MSigDB)[14], the gene set enrichment analysis (GSEA) was performed to analyze the KEGG pathways and Hallmark gene sets between different groups via the R 'clusterprofiler' package (https://bioconductor.org/packages/release/bioc/html/clusterProfiler.html). The protein-protein interaction (PPI) network diagrams of differentially expressed genes (DEGs) were drawn using the Cytoscape software (https://cytoscape.org/).
Tumor immune micro-environment analysis
The Microenvironment Cell Populations-counter (MCP-counter), CIBERSORT, and Xcell algorithms assessed the abundance of immune cells among different groups. The immune score, stroma score, and microenvironment score were computed using the R package 'Xcell' (https://github.com/dviraran/xCell). Correlations among the expression levels of CaMKⅡ and FAK and measurments of different immune checkpoints were calculated using Spearman's correlation analysis.
Statistical analysis
All data were presented as the mean ± standard deviation from three independent experiments. Statistical significance was performed using either one-way ANOVA with a Bonferroni post hoc test or Student's t-test. All statistical analyses were performed with GraphPad version 9.0 software (GraphPad Software, San Diego, CA, USA). For bioinformatics analysis, statistical analysis was performed by R (version 4.0.1, https://www.r-project.org/). Wilcoxon rank-sum test was used to compare the two groups. The Kruskal-Wallis test was applied to compare multiple groups. Spearman correlation analysis was used for correlation analysis. P < 0.05 was considered statistically significant.
Results
Calcium ions induced morphological changes and enhanced the epithelial-mesenchymal transition in HepG2 cells
To study the roles of extracellular calcium on HepG2 cells, we added additional different concentrations of CaCl2 to cells' regular medium (the DMEM medium supplemented with 10% FBS). As shown in Fig. 1A and 1B, HepG2 cells grew in the form of cell mass, then generated cell protrusions after the addition of CaCl2, and spread out with the increase of CaCl2 treatment time. In addition, morphological changes in HepG2 cells were more profound at higher concentrations of 6.25, 12.5, and 25 mmol/L CaCl2 than at 1.56 and 3.13 mmol/L CaCl2. Notably, the addition of MgCl2 and KCl could not induce the altered morphology of HepG2 cells (Fig. 1C). Moreover, when the extra addition of CaCl2 was removed, the changed morphology was reversed. Therefore, it was the calcium ions that changed the morphology of HepG2 cells (Fig. 1C).
Figure
1.
Calcium ions induced the morphological changes and enhanced the epithelial-mesenchymal transition in HepG2 cells.
A: HepG2 cells were treated with indicated concentrations of CaCl2 for different times. Representative images of HepG2 cells were observed by optical microscope (Scale bar, 200 μm). B: Percentage of cell area at different times after treatment with or without calcium. **P < 0.01 and ***P < 0.001, compared with 3 h treatment in each treated calcium concentration; #P < 0.05, ##P < 0.01, and ###P < 0.001, compared with control group in each treatment time. C: HepG2 cells were treated with or without 6.25 mmol/L CaCl2 or MgCl2 or KCl (6.25 and 12.5 mmol/L) for 24 h. The group of ± CaCl2 represents HepG2 cells treated with 6.25 mmol/L CaCl2 for 24 h and then cultured without additional CaCl2 in the regular medium for another 24 h. Representative images of HepG2 cells were observed by optical microscope (Scale bar, 200 μm). D: Quantitative real-time PCR for various adhesion-related molecules in HepG2 cells treated with or without CaCl2 at 6 h. E and F: The expression of epithelial-mesenchymal transition (EMT) markers (E-cadherin, N-cadherin and vimentin) , and Twist on CaCl2-treated (6.25 mmol/L) HepG2 cells was detected by Western blotting analysis. Data are presented as mean ± standard deviation from three independent experiments. ***P < 0.001 vs. the 0 h group. G: MCF-7, Caco-2, and HUVEC cell lines were treated with or without 6.25 and 12.5 mmol/L CaCl2 for 24 h. Representative images of the cells were observed by optical microscope (Scale bar, 200 μm). H and I: EMT markers on CaCl2-treated MCF-7, Caco-2, and HUVEC cells were analyzed by Western blotting. Cells in the Ctrl group were treated with ddH2O, compared with the cells with CaCl2 , MgCl2 or KCl treatment. Data are presented as mean ± standard deviation from three independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. the control (Ctrl) group.
As we all know, the epithelial-mesenchymal transition (EMT) plays a key role in the development of cell motility and invasiveness. We examined the mRNA expression levels of adhesion-related molecules by qRT-PCR. As shown in Fig. 1D, CaCl2 increased ITGA2 and ITGB5 mRNA levels, but decreased TIMP3, SMA, FSP1, ANGPTL, and LDHA mRNA levels, compared with the control group. In addition, we investigated the ability of calcium ions to alter markers of EMT in HepG2 cells, and found that the addition of calcium ions reduced the epithelial marker E-cadherin from 12 to 72 h (Fig. 1E and 1F), with the lowest level at 48 h. Meanwhile, the mesenchymal markers (N-cadherin and vimentin) and transcription factor Twist were significantly increased, compared with the control group (Fig. 1E and 1F). These indicate that extracellular calcium ions may mediate HepG2 cell motility by initiating the EMT. Furthermore, we examined the effects of calcium ions on other tumor and normal cells. As a result, the addition of CaCl2 did not induce noticeable morphological alterations in MCF-7, Caco-2, and HUVEC cell lines (Fig. 1G). Correspondingly, it did not simultaneously reduce the epithelial marker E-cadherin and increase the mesenchymal markers (N-cadherin and vimentin) (Fig. 1H and Fig. 1I). The results indicate that extracellular calcium may alter HepG2 cell morphology by initiating the EMT.
Calcium ions promoted HepG2 cell proliferation and migration
To determine whether extracellular calcium ions affect the malignant biological behavior of HepG2 cells, we analyzed the proliferation and migration of HepG2 cells in the presence or absence of CaCl2. CCK8 assays showed that CaCl2 dose-dependently promoted HepG2 cell viability, when the concentration of additional CaCl2 was between 0 and 6.25 mmol/L (Fig. 2A). When the CaCl2 concentration continued to increase, its effect on HepG2 began to decrease, showing a relative inhibitory effect at 25 mmol/L (Fig. 2A). According to these results, the concentration of 6.25 mmol/L CaCl2 was used for subsequent experiments. The CCK8 assay (Fig. 2B) showed that the proliferation of HepG2 cells was increased by the treatment of CaCl2. Moreover, the EdU assay was also used to detect the effect of CaCl2 on cell proliferation. As shown in Fig. 2C, the number of EdU positive cells increased clearly after CaCl2 treatment for 24 h. The effect of CaCl2 on HepG2 cell migration was examined by using wound healing assays. As shown in Fig. 2D and 2E, CaCl2 could promote HepG2 cell migration, compared with the control group. Taken together, these results reveal that calcium ions can promote HepG2 cell proliferation within a certain range of concentrations and enhance HepG2 cell migration.
Figure
2.
Calcium ions promoted HepG2 cell proliferation and migration and changed the phosphorylation levels of multiple proteins.
A: HepG2 cells were treated with indicated concentrations of CaCl2 for 24 h. Cell proliferation was assessed using the CCK8 assay. B: HepG2 cells were treated with 6.25 mmol/L CaCl2 for 12, 24, and 48 h. Cell proliferation was assessed using the CCK8 assay. C: HepG2 cells were treated with CaCl2 for 24 h. Cell proliferation was assessed using EdU proliferation assay. Scale bar, 200 μm. D and E: Wound healing assays were used to detect cell migration. Scale bar, 400 μm. F and G: Total protein was extracted, the phosphorylation of FAK, AKT, p38, p65, ERK, and STAT3 were detected using Western blotting. Cells in the Ctrl group were treated with ddH2O, compared with the cells with CaCl2 treatment. Data are presented as mean ± standard deviation from three independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. the control (Ctrl) group.
To investigate the signaling pathways involved in the CaCl2-mediated effect on HepG2 cell proliferation and migration, we detected the phosphorylation levels of FAK, protein kinase B (AKT), p38 mitogen-activated protein kinase, nuclear factor kappa-B (NF-κB) p65, extracellular signal-regulated kinase (ERK), and signal transducer and activator of transcription 3 (STAT3) by Western blotting. The data indicated that the phosphorylation level of FAK was obviously enhanced in response to CaCl2 treatment at 3 h and then decreased at 48 and 72 h (Fig. 2F and 2G). Phosphorylation of AKT was significantly increased 6 h after the addition of CaCl2, and p38 phosphorylation was increased 3 h after treatment of CaCl2. Meanwhile, phosphorylation of p65 and ERK was impaired 12 h after CaCl2 treatment, and the phosphorylation level of STAT3 was decreased 6 to 24 h after the addition of CaCl2. Therefore, the results indicate that calcium ions may promote HepG2 cell proliferation and migration by regulating the phosphorylation levels of FAK, AKT, p38, p65, ERK, and STAT3.
Calcium ions promoted HepG2 cell proliferation and migration by enhancing the activation of FAK-AKT signaling pathways
The inhibitor of FAK (PF573228), calpeptin (MDL28170), ATPase [(-)-blebbistatin], actin polymers (cytochalasin B), mitosis (nocodazole), and ROCK (Y-27632) were used to explore possible mechanisms involved. We found that the changed morphology of HepG2 cells was reversed, when pretreated with PF573228 (10 µmol/L) for 1 h, and then stimulated with CaCl2 for 12 h (Fig. 3A). No similar inhibitory effects were observed, when the cells were pretreated with the other five compounds associated with cells mobility (Fig. 3A). These results are consistent with those of a previous study[15]. Next, two doses (5 and 10 µmol/L) of PF573228 were used to treat cells. As shown in Fig. 3B, the effect of PF573228 was concentration-dependent, and a 5 µmol/L dose was used for subsequent experiments due its obvious inhibitory effects.
Figure
3.
Calcium ions promoted HepG2 cell proliferation and migration by enhancing the activation of FAK-AKT signaling pathways.
A: HepG2 cells were pretreated with six different compounds (final concentration, 10 μmol/L) for 1 h, cells in the Ctrl group were treated with 0.1% DMSO for 1 h, and then stimulated with or without CaCl2 for 12 h, the morphology of cells was observed using the optical microscope (Scale bar, 400 μm). B: Different doses (5 and 10 μmol/L) of PF573228 were used to pretreat HepG2 cells, cells in the Ctrl group were treated with 0.1% DMSO, and the morphology of cells was observed using the optical microscope (Scale bar, 200 μm). C–E: HepG2 cells were pretreated with or without 5 μmol/L PF573228 (or 0.1% DMSO in the Ctrl group) for 1 h and then treated with CaCl2 for 12 or 48 h, the proliferation abilities were detected using CCK8 (C) and EdU assays (D), cell migration was detected using the wound healing assay (E–F). Scale bar, 200 μm (D) and 400 μm (E). G–J: Western blotting analyzed the expression of E-cadherin, N-cadherin, and vimentin (G and H), and phosphorylation levels of FAK and AKT (I and J). Data are presented as mean ± standard deviation from three independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.001.
As shown in Fig. 3C, PF573228 pretreatment clearly reduced HepG2 cell proliferation, compared with the cells treated with CaCl2. The same results were verified by the EdU assay (Fig. 3D). The wound healing assay showed that PF573228 reversed the promoted effects of CaCl2 on cell migration (Fig. 3E and 3F). Moreover, we found that PF573228 pre-treatment reversed the CaCl2-induced changes in expression levels of EMT marker proteins (Fig. 3G and 3H). At the same time, the addition of PF573228 clearly decreased the phosphorylation levels of FAK and AKT, compared with CaCl2 alone (Fig. 3I and Fig. 3J). Overall, the results suggest that calcium ions may promote HepG2 cell proliferation and migration by enhancing the activation of FAK-AKT signaling pathway.
Calcium ions promoted HepG2 cells proliferation and migration via CaMKⅡ-FAK-AKT signaling pathway
Next, the upstream factors regulating the phosphorylation of FAK were investigated. It has been described that CaMKⅡ regulates cell motility by stimulating tyrosine dephosphorylation of focal adhesion proteins to promote focal adhesion turnover[16]. Thus, CaMKⅡ may be an upstream factor that regulates the phosphorylation of FAK. Therefore, we used KN93, the inhibitor of CaMKⅡ, to pretreat HepG2 cells with different concentrations (5 and 10 μmol/L). The data showed that KN93 inhibited the effect of CaCl2 in a concentration-dependent manner (Fig. 4A), and 5 μmol/L of KN93 was chosen for the subsequent experiments due to its obvious reversal effect.
Figure
4.
Calcium ions promoted HepG2 cell proliferation and migration via CaMKⅡ-FAK-AKT signaling pathway.
A: HepG2 cells were pretreated with different concentrations of KN93 (5 and 10 μmol/L) for 1 h, cells in the Ctrl group were treated with 0.1% DMSO for 1 h, and then stimulated with or without CaCl2 for 12 h, the morphology of cells was observed using the optical microscope (Scale bar, 200 μm). B–D: HepG2 cells were pretreated with or without KN93 (or 0.1% DMSO in the Ctrl group) for 1 h and then treated with CaCl2 for 12 or 48 h, the proliferation abilities were detected using CCK8 (B) and EdU assays (C), cell migration was detected using the wound healing assay (D and E). Scale bar, 200 μm (C) and 400 μm (D). F–I: The expression of EMT markers (F) and phosphorylation of FAK and AKT (H) were detected using Western blotting. Data are presented as mean ± standard deviation from three independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. the control (Ctrl) group.
As shown in Fig. 4B, cell proliferation abilities were reduced with KN93 pretreatment, compared without KN93 pretreatment. The same results were achieved with the EdU assay (Fig. 4C). Next, we analyzed the effect of KN93 on migration abilities of HepG2 cells by the wound healing assay. The migration of HepG2 cells was significantly inhibited in the presence of KN93, compared without KN93 pretreatment (Fig. 4D and 4E). In addition, KN93 pretreatment reversed EMT induced by CaCl2 and reduced the phosphorylation levels of FAK and AKT, compared with CaCl2 treated alone (Fig. 4F–4I). Collectively, these results indicate that CaMKⅡ is the upstream factor regulating the phosphorylation of FAK. Hence, calcium ions may promote HepG2 cell proliferation and migration via the CaMKⅡ-FAK-AKT signaling pathway.
Calcium ions decreased HepG2 cells' sensitivity to cisplatin
Next, we investigated the effect of CaCl2 on cisplatin-induced cell death. HepG2 cells pre-treated with CaCl2 showed an obviously reduced proportion with typical apoptotic features, such as rounding, shrinkage, and detachment (Fig. 5A). The quantification of cell viability by the CCK8 assay showed that the inhibition rate of cisplatin was reduced by 20.34 percentage points in the group of CaCl2 + cisplatin, compared with cisplatin alone (Fig. 5B). To further confirm the decrease in the inhibition rate, survival cells were counted. As shown in Fig. 5C, the cells treated with cisplatin in the presence of CaCl2 showed a reduced inhibition rate (50.47% vs. 29.34%), compared with the cisplatin group, suggesting that calcium ions decreased HepG2 cells' sensitivity to cisplatin.
Figure
5.
Calcium ions decreased the cisplatin sensitivity of HepG2 cells.
HepG2 cells were pretreated with CaCl2 (or ddH2O in the Ctrl group) for 24 h, and then stimulated with or without 5 μmol/L cisplatin (or 0.1% DMSO in the Ctrl group) for 24 h. A: The morphology of cells was observed using the optical microscope. Scale bar, 200 μm. B and C: Cell viability and survival cells were detected using CCK8 assay (B) and hemocytometer (C). Inhibition rate of the Ctrl group = [(Aa − Ab) / Aa] × 100%; inhibition rate of the CaCl2-pretreatment group = [(Ac − Ad) / Ac] × 100% (Aa: cell viability or survival cells of the Ctrl group; Ab: cell viability or survival cells of the cisplatin group; Ac: cell viability or survival cells of the CaCl2 group; Ad: cell viability or survival cells of the CaCl2 + cisplatin group). Data are presented as mean ± standard deviation from three independent experiments. *P < 0.05, ***P < 0.001.
Characterization of FAK and CaMKⅡ expression in hepatoblastoma
To investigate the roles of FAK and CaMKⅡ in hepatoblastoma, we further analyzed RNA‐seq data and corresponding clinical information on hepatoblastoma from the GEO database. As shown in Fig. 6A, FAK mRNA expression level was significantly increased in hepatoblastoma. Similarly, CaMKⅡ was mostly increased in hepatoblastoma. Using Children's Hepatic tumor International Collaboration (CHIC) risk stratification system, we found that there was a significant difference of CaMKⅡ expression between the standard and high CHIC risk stratification groups from GSE133039 (Fig. 6B). Moreover, we combined the expression of FAK and CaMKⅡ, and categorized them as low and high groups. Intriguingly, GSEA enrichment analysis of hallmark gene sets in GSE133039 showed that the high expression of FAK and CaMKⅡ was enriched in unfolded protein response, G2M checkpoint, and DNA repair (Fig. 6C). The KEGG analysis indicated that p53 signaling pathway was enriched with high expression of FAK and CaMKⅡ (Fig. 6C). The differential expressed genes in three GEO datasets (GSE104766, GSE131309, and GSE131329) were further analyzed in groups with high and low expression of FAK and CaMKⅡ, and a total of 186 common genes were found (Fig. 6D, Supplementary Fig. 1 [available online]). The enriched KEGG pathways were identified as RNA degradation, cell cycle, and protein export, etc. (Fig. 6E). The PPI network analysis of the 186 DEGs was further explored using the Cytoscape software (Fig. 6F), and the enriched KEGG and GO pathways were analyzed (Supplementary Fig. 1B and 1C). Intriguingly, the data from GSE38122 showed that FAK expression was significantly downregulated after cisplatin treatment on HepG2 cells (Fig. 6G), and no change of CaMKⅡ expression was observed (Supplementary Fig. 1D).
Figure
6.
Characterization of FAK and CaMKⅡ expression in hepatoblastoma.
A: Relative expression of FAK and CaMKⅡ in hepatoblastoma tissue and adjacent normal tissue in GSE104766, GSE131329, GSE133039, and GSE151347 datasets. Data are presented as median and interquartile. B: CaMKⅡand FAK expression levels in the different Children's Hepatic Tumor International Collaboration (CHIC) Risk Stratification groups from GSE133039. Data are presented as median and interquartile. C: Combined expression of CaMKⅡ and FAK was categorized as low and high. GSEA enrichment analysis of hallmark gene sets and KEGG pathway in high expression group. D: Heatmaps of differentially expressed genes in three GEO datasets. E: The intersection of differential genes in three GEO datasets was identified as differentially expressed genes (DEGs) and the enriched KEGG pathways of the 186 DEGs. F: The protein-protein interaction network analysis of the 186 DEGs was drawn using the Cytoscape software. G: The relation expression of FAK in PBS or cisplatin-treated HepG2 cell line from GSE38122. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, and nsP > 0.05.
FAK and CaMKⅡ shaped immune cell infiltration and immune responses in hepatoblastoma
Furthermore, we explored the roles of FAK and CaMKⅡ in tumor microenvironment of hepatoblastoma. There were significantly lower immune and microenvironment scores observed in the group with high expression of FAK and CaMKⅡ (Fig. 7A) as well as CD8+ T and NK cells (Fig. 7B). The immune cells infiltration was further analyzed by CIBERSORT (Fig. 7C) and Xcell algorithms (Fig. 7D). More immune cells were observed in the group with low expression of FAK and CaMKⅡ (Fig. 7C and 7D). The expression of CaMKⅡ was positively correlated with that of CD70, LAG3, and PDCD1 (Fig. 7E), while FAK exhibited negative correlations (Fig. 7F). Moreover, we analyzed the correlations of FAK and CaMKⅡ with a variety of inhibitory and stimulatory molecules (Fig. 7G and 7H). Consequently, the expression of CaMKⅡ was positively correlated with that of LAG3, PDCD1, IL-4, and IL-13 (Fig. 7G), but the expression of FAK was negatively correlated with that of TNFSF9, TNFRSF4, and TNFRSF18 (Fig. 7H). Furthermore, we analyzed the expression of PD-L1 and FGL1 on HepG2 cells treated with or without CaCl2. The data showed that calcium treatment reduced PD-L1 expression at both mRNA and protein levels, compared with the control group (Fig. 7I and 7J, Supplementary Fig. 2 [available online]), while no difference in the expression of FGL1 was observed at the mRNA level (Fig. 7I).
Figure
7.
FAK and CaMKⅡ shaped immune cell infiltration and immune responses in hepatoblastoma.
A: Violin plot of immunity score, stroma score, and microenvironment score between the low and high CaMKⅡ + FAK expression groups. Data are presented as median and interquartile. B: Boxplots of the immune cell infiltration levels in the low and high CaMKⅡ + FAK expression groups used the MCP-counter algorithm. Data are presented as mean ± standard deviation. C: The heatmap of immune cells was estimated by the CIBERSORT algorithm. D: The composite thermogram shows the frequency of TME infiltrating cells among the different groups estimated by the Xcell algorithm. E and F: Scatter plot of expression correlation between CaMKⅡ or FAK with BTM3A1, CD70, LAG3, and PDCD1. G and H: The correlation between CaMKⅡ or FAK expression with inhibitory immune checkpoints (G) and immune stimulatory checkpoints (H). I: HepG2 cells were treated with or without CaCl2 for 12 h, the mRNA expression of PD-L1 and FGL1 were detected by quantitative real-time PCR. J: Flow cytometry analyzed the expression of PD-L1 on HepG2 cells treated with or without CaCl2 for 24 h. Data are presented as mean ± standard deviation (I and J). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, and nsP > 0.05.
Ca2+ is a critical regulator of various cancer processes[12,17]. Many transmembrane Ca2+ channels or pumps have abnormal expression or activities in tumor cells, facilitating oncogenesis and tumor progression[18–19]. Previously, several studies have found that overexpression of transmembrane Ca2+ channels increases Ca2+ influx and stimulates intracellular Ca2+-involved proliferative pathways[20–21]. In the present study, extracellular calcium ions were shown to induce the morphology and adhesion molecule changes of HepG2 cells. However, similar changes were not found in other cancer cells, such as MCF-7, Caco-2, and HUVEC cells. It is possible that different cells respond differently to the treatment with extracellular calcium ions.
The microenvironment of both primary tumors and corresponding metastatic sites is a critical element in tumor progression[22]. Ca2+ signal represents a potential means through which tumor microenvironment signals to cancer cells[23–24]. The role of Ca2+ signals in multiple cell types is still relatively unclear. Studies have demonstrated that Ca2+ signal interacts with many microenvironmental factors. For example, the acidic characteristics of tumor microenvironment alters free Ca2+ levels via the acid-sensing ion channel 1 (ASIC1), which causes the induction of reactive oxygen species and the activation of NF-κB in breast cancer cells[24]. In addition, a high level of extracellular Ca2+ is a driver for bone metastasis in cancers, which expresses the extracellular calcium-sensing receptor (CaSR)[25]. Here, we demonstrated that extracellular calcium ions promoted HepG2 cell proliferation and migration within a suitable concentration range. High calcium ion concentration caused cell death, which may be related to cytosolic calcium overload[26]. Moreover, high calcium ion concentration can cause excessive mitochondrial calcium uptake, resulting in the release of cytochrome C and other pro-apoptotic factors[27]. A better understanding of both in intracellular and extracellular calcium ions may provide new insights into disease progression.
FAK, a non-receptor tyrosine kinase, was found to be activated and up-regulated in gliomas[28]. According to a previous study, the activated FAK could activate PI3K, and the activated PI3K would in turn activate AKT that regulated cell growth and movement[29]. In the present study, we consistently found that calcium ions increased the levels of p-FAK and p-AKT in HepG2 cells, and the inhibitor of FAK reduced the level of p-AKT.
Ca2+/calmodulin (CaM)-dependent kinases belong to a family of multifunctional serine/threonine kinases regulated by the Ca2+/CaM complex[30]. A recent study showed that the CaMKⅡ-regulated signaling also played a role in carcinogenesis[31], and CaMKⅡ could phosphorylate several proteins involved in migration and invasion, including FAK[32]. Our results showed that the KN-93-mediated pharmacological inhibition of CaMKⅡ activity decreased the phosphorylation levels of FAK and AKT. Taken together, these findings indicate that the activation of the CaMKⅡ/FAK/AKT signaling axis plays an important role in the effects of calcium ions on HepG2 cell proliferation and migration. In addition, as the level of p-p38 was up-regulated and the levels of p-p65, p-ERK, and p-STAT3 were down-regulated, calcium ions may also regulate these signaling pathways to promote HepG2 cell growth, but these phenomina need to be clarified by further studies.
Furthermore, we compressively analyzed the roles of FAK and CaMKⅡ in hepatoblastoma, because their expression levels were significantly increased in hepatoblastoma. In addition, we found that FAK and CaMKⅡ shaped immune cell infiltration and immune responses in hepatoblastoma. Moreover, CaMKⅡ expression was positively correlated with some inhibitory molecules, but FAK expression was negatively correlated with some stimulatory molecules. Together, these suggest that FAK and CaMKⅡ may play critical roles in regulating tumor immune microenvironment. The influx and efflux of Ca2+ are controlled by a diverse array of calcium channels and pumps as well as exchangers present on the plasma membrane and membranes of intracellular organelles[23]. The limitation of the present study is that we did not determine which calcium channel was involved in the effect of calcium ions on HepG2 cells. The blockers of calcium transporters warrant further investigations. Moreover, chelation therapy may need to be explored for hepatoblastoma treatment or immunotherapy.
Cisplatin is frequently applied as the first-line chemotherapeutic agent in the clinic against a wide spectrum of cancers[33]. It may exhibit cytotoxic properties and induce apoptosis by binding to DNA. However, cisplatin resistance has become one of the major medical problems for its valid treatment against malignancies[34]. It is unclear whether calcium ions may cause changes in cisplatin resistance in HepG2 cells, but we showed that calcium ions increased cisplatin resistance of HepG2 cells, which provides new insights into antitumor therapy.
Taken together, we found that the elevated calcium ions altered the morphology and expression level of adhesion molecules in HepG2 cells. Mechanistically, calcium ions promoted HepG2 proliferation and migration mainly by activating the CaMKⅡ-FAK-AKT signaling pathway. Moreover, FAK and CaMKⅡ shaped tumor immune environment by influencing immune cells and immune checkpoints. Calcium ions could also increase cisplatin resistance in HepG2 cells. Collectively, targeting calcium signaling and FAK and CaMKⅡ molecules may serve as new therapeutic tools to treat hepatoblastoma.
Acknowledgments
None.
Fundings
This research was funded by the Jiangsu Medical Scientific Research Project of Jiangsu Health Commission (to Q.Y.), the 789 Outstanding Talent Program of SAHNMU (Grant No. 789ZYRC202070102 to Q.Y.), the Guangzhou Key Medical Discipline Construction Project (to Q.Y.), and the National Natural Science Foundation of China (Grant Nos. 81870409 and 81671543 to Q.Y.).
Lim IIP, Bondoc AJ, Geller JI, et al. Hepatoblastoma-the evolution of biology, surgery, and transplantation[J]. Children, 2018, 6(1): 1. doi: 10.3390/children6010001
[2]
Kehm RD, Osypuk TL, Poynter JN, et al. Do pregnancy characteristics contribute to rising childhood cancer incidence rates in the United States?[J]. Pediatr Blood Cancer, 2018, 65(3): e26888. doi: 10.1002/pbc.26888
Feng J, Polychronidis G, Heger U, et al. Incidence trends and survival prediction of hepatoblastoma in children: a population-based study[J]. Cancer Commun, 2019, 39(1): 1–9. doi: 10.1186/s40880-018-0346-4
[5]
Kremer N, Walther AE, Tiao GM. Management of hepatoblastoma: an update[J]. Curr Opin Pediatr, 2014, 26(3): 362–369. doi: 10.1097/MOP.0000000000000081
[6]
Warmann SW, Fuchs J. Drug resistance in hepatoblastoma[J]. Curr Pharm Biotechnol, 2007, 8(2): 93–97. doi: 10.2174/138920107780487456
[7]
Arzumanian VA, Kiseleva OI, Poverennaya EV. The curious case of the HepG2 cell line: 40 years of expertise[J]. Int J Mol Sci, 2021, 22(23): 13135. doi: 10.3390/ijms222313135
[8]
López-Terrada D, Cheung SW, Finegold MJ, et al. Hep G2 is a hepatoblastoma-derived cell line[J]. Hum Pathol, 2009, 40(10): 1512–1515. doi: 10.1016/j.humpath.2009.07.003
Yang Z, Yue Z, Ma X, et al. Calcium homeostasis: a potential vicious cycle of bone metastasis in breast cancers[J]. Front Oncol, 2020, 10: 293. doi: 10.3389/fonc.2020.00293
[11]
Roderick HL, Cook SJ. Ca2+ signalling checkpoints in cancer: remodelling Ca2+ for cancer cell proliferation and survival[J]. Nat Rev Cancer, 2008, 8(5): 361–375. doi: 10.1038/nrc2374
[12]
Prevarskaya N, Skryma R, Shuba Y. Calcium in tumour metastasis: new roles for known actors[J]. Nat Rev Cancer, 2011, 11(8): 609–618. doi: 10.1038/nrc3105
[13]
Liu Z, Wang L, Xu H, et al. Heterogeneous responses to mechanical force of prostate cancer cells inducing different metastasis patterns[J]. Adv Sci, 2020, 7(15): 1903583. doi: 10.1002/advs.201903583
[14]
Liberzon A, Birger C, Thorvaldsdottir H, et al. The molecular signatures database hallmark gene set collection[J]. Cell Syst, 2015, 1(6): 417–425. doi: 10.1016/j.cels.2015.12.004
[15]
Yang N, Tang Y, Wang F, et al. Blockade of store-operated Ca2+ entry inhibits hepatocarcinoma cell migration and invasion by regulating focal adhesion turnover[J]. Cancer Lett, 2013, 330(2): 163–169. doi: 10.1016/j.canlet.2012.11.040
[16]
Easley IV CA, Brown CM, Horwitz AF, et al. CaMK-II promotes focal adhesion turnover and cell motility by inducing tyrosine dephosphorylation of FAK and paxillin[J]. Cell Motil Cytoskeleton, 2008, 65(8): 662–674. doi: 10.1002/cm.20294
[17]
Patergnani S, Danese A, Bouhamida E, et al. Various aspects of calcium signaling in the regulation of apoptosis, autophagy, cell proliferation, and cancer[J]. Int J Mol Sci, 2020, 21(21): 8323. doi: 10.3390/ijms21218323
[18]
Marchi S, Giorgi C, Galluzzi L, et al. Ca2+ fluxes and cancer[J]. Mol Cell, 2020, 78(6): 1055–1069. doi: 10.1016/j.molcel.2020.04.017
[19]
Roberts-Thomson SJ, Chalmers SB, Monteith GR. The calcium-signaling toolkit in cancer: remodeling and targeting[J]. Cold Spring Harb Perspect Biol, 2019, 11(8): a035204. doi: 10.1101/cshperspect.a035204
[20]
Wu L, Lian W, Zhao L. Calcium signaling in cancer progression and therapy[J]. FEBS J, 2021, 288(21): 6187–6205. doi: 10.1111/febs.16133
[21]
Koivisto AP, Belvisi MG, Gaudet R, et al. Advances in TRP channel drug discovery: from target validation to clinical studies[J]. Nat Rev Drug Discov, 2022, 21(1): 41–59. doi: 10.1038/s41573-021-00268-4
[22]
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646–674. doi: 10.1016/j.cell.2011.02.013
[23]
Monteith GR, Prevarskaya N, Roberts-Thomson SJ. The calcium-cancer signalling nexus[J]. Nat Rev Cancer, 2017, 17(6): 373–380. doi: 10.1038/nrc.2017.18
[24]
Gupta SC, Singh R, Asters M, et al. Regulation of breast tumorigenesis through acid sensors[J]. Oncogene, 2016, 35(31): 4102–4111. doi: 10.1038/onc.2015.477
[25]
Joeckel E, Haber T, Prawitt D, et al. High calcium concentration in bones promotes bone metastasis in renal cell carcinomas expressing calcium-sensing receptor[J]. Mol Cancer, 2014, 13: 42. doi: 10.1186/1476-4598-13-42
[26]
Zhivotovsky B, Orrenius S. Calcium and cell death mechanisms: a perspective from the cell death community[J]. Cell Calcium, 2011, 50(3): 211–221. doi: 10.1016/j.ceca.2011.03.003
[27]
Sukumaran P, Da Conceicao VN, Sun Y, et al. Calcium signaling regulates autophagy and apoptosis[J]. Cells, 2021, 10(8): 2125. doi: 10.3390/cells10082125
[28]
Ding LS, Sun XY, You YP, et al. Expression of focal adhesion kinase and phosphorylated focal adhesion kinase in human gliomas is associated with unfavorable overall survival[J]. Transl Res, 2010, 156(1): 45–52. doi: 10.1016/j.trsl.2010.05.001
[29]
Teutschbein J, Schartl M, Meierjohann S. Interaction of Xiphophorus and murine Fyn with focal adhesion kinase[J]. Comp Biochem Physiol C Toxicol Pharmacol, 2009, 149(2): 168–174. doi: 10.1016/j.cbpc.2008.09.013
[30]
Peng JM, Tseng RH, Shih TC, et al. CAMK2N1 suppresses hepatoma growth through inhibiting E2F1-mediated cell-cycle signaling[J]. Cancer Lett, 2021, 497: 66–76. doi: 10.1016/j.canlet.2020.10.017
[31]
Chen W, An P, Quan X, et al. Ca2+/calmodulin-dependent protein kinase II regulates colon cancer proliferation and migration via ERK1/2 and p38 pathways[J]. World J Gastroenterol, 2017, 23(33): 6111–6118. doi: 10.3748/wjg.v23.i33.6111
[32]
Lu KK, Armstrong SE, Ginnan R, et al. Adhesion-dependent activation of CaMKII and regulation of ERK activation in vascular smooth muscle[J]. Am J Physiol Cell Physiol, 2005, 289(5): C1343–C1350. doi: 10.1152/ajpcell.00064.2005
[33]
Wang Y, Liu Y, Liu Y, et al. A polymeric prodrug of cisplatin based on pullulan for the targeted therapy against hepatocellular carcinoma[J]. Int J Pharm, 2015, 483(1–2): 89–100. doi: 10.1016/j.ijpharm.2015.02.027
[34]
Huang C, Chen JYF, Wu J, et al. Ling-Zhi polysaccharides potentiate cytotoxic effects of anticancer drugs against drug-resistant urothelial carcinoma cells[J]. J Agric Food Chem, 2010, 58(15): 8798–8805. doi: 10.1021/jf1020158
Braghini MR, De Stefanis C, Tiano F, et al. Focal adhesion kinase and its epigenetic interactors as diagnostic and therapeutic hints for pediatric hepatoblastoma. Front Oncol, 2024, 14: 1397647.
DOI:10.3389/fonc.2024.1397647
1.
Braghini MR, De Stefanis C, Tiano F, et al. Focal adhesion kinase and its epigenetic interactors as diagnostic and therapeutic hints for pediatric hepatoblastoma. Front Oncol, 2024, 14: 1397647.
DOI:10.3389/fonc.2024.1397647
Authors and Reviewers
DownLoad:
